{"corpus_id":205688489,"paper_sha":"9f75bba8e201b2dc9c95d7dbb0942f0489c8e1b2","doi":"10.1002/cpdd.411","arxiv_id":null,"pmid":29112329,"pmcid":"5900965","mag_id":2767852989,"dblp_id":null,"acl_id":null,"title":"In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF‐00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor","year":2017,"publication_date":"2017-11-07","venue":"Clinical pharmacology in drug development","journal":{"name":"Clinical Pharmacology in Drug Development","pages":"244 - 255","volume":"7"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle","ClinicalTrial"],"pubmed_pub_types":["Clinical Trial, Phase I","Journal Article","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine","Chemistry"],"reference_count":33,"citation_count":4,"influential_citation_count":0,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Cytochrome P-450 CYP3A","mj":false,"qs":[{"q":"metabolism","mj":true,"ui":"Q000378"}],"ui":"D051544"},{"d":"Drug Interactions","mj":false,"qs":[{"q":"physiology","mj":false,"ui":"Q000502"}],"ui":"D004347"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Microsomes, Liver","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"},{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D008862"},{"d":"Midazolam","mj":false,"qs":[{"q":"metabolism","mj":true,"ui":"Q000378"},{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D008874"},{"d":"Organophosphates","mj":false,"qs":[{"q":"chemistry","mj":false,"ui":"Q000737"},{"q":"metabolism","mj":true,"ui":"Q000378"},{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D010755"},{"d":"Phenanthrenes","mj":false,"qs":[{"q":"chemistry","mj":false,"ui":"Q000737"},{"q":"metabolism","mj":true,"ui":"Q000378"},{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D010616"},{"d":"Prodrugs","mj":false,"qs":[{"q":"chemistry","mj":false,"ui":"Q000737"},{"q":"metabolism","mj":true,"ui":"Q000378"},{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D011355"},{"d":"Receptors, Glucocorticoid","mj":false,"qs":[{"q":"agonists","mj":true,"ui":"Q000819"},{"q":"metabolism","mj":true,"ui":"Q000378"}],"ui":"D011965"},{"d":"Benzamides","mj":false,"ui":"D001549"}],"chemicals":[{"n":"Cytochrome P-450 CYP3A","ui":"D051544","reg":"EC 1.14.14.1"},{"n":"Midazolam","ui":"D008874","reg":"R60L0SM5BC"},{"n":"Organophosphates","ui":"D010755","reg":"0"},{"n":"Phenanthrenes","ui":"D010616","reg":"0"},{"n":"Prodrugs","ui":"D011355","reg":"0"},{"n":"Receptors, Glucocorticoid","ui":"D011965","reg":"0"},{"n":"CYP3A protein, human","ui":"C104464","reg":"EC 1.14.14.1"},{"n":"fosdagrocorat","ui":"C000615597","reg":"HPI19004QS"},{"n":"Benzamides","ui":"D001549","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.411","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/9f75bba8e201b2dc9c95d7dbb0942f0489c8e1b2","s2_open_access_license":"CCBYNCND","s2_open_access_status":"HYBRID","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"The dissociated agonists of the glucocorticoid receptor are a novel class of agents in clinical development for rheumatoid arthritis. PF‐04171327 (fosdagrocorat) is a phosphate ester prodrug of PF‐00251802 (dagrocorat), a selective high‐affinity partial agonist of the glucocorticoid receptor, which is further metabolized to PF‐04015475. This study evaluated the cytochrome P450 (CYP)–mediated drug–drug interaction (DDI) potential of PF‐00251802 and PF‐04015475 in vitro and used model‐based prediction approaches to estimate clinical impact. PF‐00251802 is a reversible inhibitor of several CYPs, but modeling has suggested no clinically relevant interaction. PF‐00251802 and PF‐04015475 are time‐dependent inhibitors and inducers of CYP3A in vitro; PF‐00251802 is also a time‐dependent inhibitor of CYP2D6. Model‐based prediction suggested the potential for weak inhibition of CYP3A in vivo. A clinical DDI study was conducted with midazolam, a sensitive CYP3A substrate. A phase 1 open‐label, multiple‐dose study evaluated the effect of PF‐04171327 on midazolam pharmacokinetics and safety in 12 healthy volunteers. Administration of midazolam alone or concomitantly with PF‐04171327 resulted in equivalent pharmacokinetic profiles (AUCinf, 21.17 vs 20.28 ng·h/mL, respectively), indicating that PF‐04171327 had no net effect on CYP3A activity in vivo. These findings support the further development of PF‐00251802 and PF‐04171327 as potential treatments for patients with rheumatoid arthritis (NCT00987038).","claims":[{"public_id":"cl_e4c175a90ecef92dde158101774ef95c","status":"active","text":"Model-based prediction suggested only weak CYP3A inhibition in vivo for PF-00251802.","confidence":0.91,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_e4c175a90ecef92dde158101774ef95c"},{"public_id":"cl_560ea9c9591dd7ecf5af22aa5a5392db","status":"active","text":"PF-00251802 and PF-04015475 act as time-dependent inhibitors and inducers of CYP3A in vitro, and PF-00251802 is also a time-dependent inhibitor of CYP2D6.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_560ea9c9591dd7ecf5af22aa5a5392db"},{"public_id":"cl_8fd185c82c63250b1b825d6ba4216c63","status":"active","text":"PF-04171327 had no net effect on CYP3A activity in vivo, as midazolam pharmacokinetic profiles were equivalent with and without coadministration.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_8fd185c82c63250b1b825d6ba4216c63"}],"concepts":[{"public_id":"co_0c1c97e84c0abf673c0cccc0d17a8ed4","status":"active","name":"PF-00251802","description":"Dagrocorat, a selective high-affinity partial agonist of the glucocorticoid receptor and the parent compound evaluated for cytochrome P450 interactions.","types":["compound"],"aliases":["dagrocorat"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0c1c97e84c0abf673c0cccc0d17a8ed4"},{"public_id":"co_1cb56ac45660925e31504d056ef21d46","status":"active","name":"CYP3A","description":"A cytochrome P450 enzyme family involved in drug metabolism and substrate clearance.","types":["enzyme"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1cb56ac45660925e31504d056ef21d46"},{"public_id":"co_2a063f157458d1e7b888e39f927bc9cf","status":"active","name":"cytochrome P450-mediated drug-drug interaction","description":"Potential interaction between drugs arising from effects on cytochrome P450 enzymes.","types":["pharmacokinetic interaction"],"aliases":["CYP-mediated DDI","DDI"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2a063f157458d1e7b888e39f927bc9cf"},{"public_id":"co_30fcbf6bda139d4586a19f3b383237cb","status":"active","name":"dissociated agonists of the glucocorticoid receptor","description":"A class of glucocorticoid receptor ligands developed to separate desired anti-inflammatory effects from some adverse effects.","types":["drug class"],"aliases":["dissociated agonists"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_30fcbf6bda139d4586a19f3b383237cb"},{"public_id":"co_651048792f3e208cf46f9dc851cd0630","status":"active","name":"PF-04015475","description":"A metabolite of PF-00251802 evaluated in the drug-interaction assessment.","types":["metabolite","compound"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_651048792f3e208cf46f9dc851cd0630"},{"public_id":"co_7bf1ecab86416e7f77bd2ffbb6974b2a","status":"active","name":"glucocorticoid receptor","description":"A steroid hormone receptor targeted by glucocorticoid agonists.","types":["receptor"],"aliases":["GR"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7bf1ecab86416e7f77bd2ffbb6974b2a"},{"public_id":"co_7c71d3fc9e82db4ce48fa322aea3093b","status":"active","name":"model-based prediction approaches","description":"Computational methods used to estimate the likely clinical impact of enzyme-mediated drug interactions.","types":["method"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7c71d3fc9e82db4ce48fa322aea3093b"},{"public_id":"co_b5e32a26d43f7c9f519fb3bf551d3ccb","status":"active","name":"PF-04171327","description":"Fosdagrocorat, a phosphate ester prodrug of PF-00251802.","types":["prodrug","compound"],"aliases":["fosdagrocorat"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b5e32a26d43f7c9f519fb3bf551d3ccb"},{"public_id":"co_c44fcdfdd3ca2028a64dd7f1164441e4","status":"active","name":"CYP2D6","description":"A cytochrome P450 enzyme involved in metabolism of many drugs.","types":["enzyme"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c44fcdfdd3ca2028a64dd7f1164441e4"},{"public_id":"co_f1916663019bc4d93fb2b5b562219777","status":"active","name":"midazolam","description":"A sensitive CYP3A substrate used as the probe drug in the clinical interaction study.","types":["drug","probe substrate"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_f1916663019bc4d93fb2b5b562219777"}],"external_ids":{"DOI":"10.1002/cpdd.411","ArXiv":null,"PubMed":29112329,"PubMedCentral":"5900965","MAG":2767852989,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.411","landing_url":"https://www.semanticscholar.org/paper/9f75bba8e201b2dc9c95d7dbb0942f0489c8e1b2","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNCND","status":"HYBRID","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632361,"paper_uid":"c2e511b6-01ec-4c1a-a696-c6dcf5278cf9","canonical_identity":{"paper_id":632361,"paper_uid":"c2e511b6-01ec-4c1a-a696-c6dcf5278cf9","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/205688489"}